Effectiveness of CBD for Neuropathic Pain in Diabetic Foot Neuropathy

NACompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

June 30, 2025

Conditions
Xerosis CutisNeuropathic Pain Associated With Diabetic Peripheral Neuropathy
Interventions
DRUG

Group 1. Complete formula

After fulfilling the criteria and agreeing to participate in the study, patients who were included in group 1 after randomisation were evaluated and received a topical cream with cannabidiol, Urea 10%, arnica and menthol as active ingredients. After one month of application of the formula, a second evaluation was carried out.

DRUG

Group 2. Cannabidiol and Urea 10% formula.

After meeting the criteria and agreeing to participate in the study, the patients who were included in group 2 after randomisation were evaluated and received a topical cream containing cannabidiol and 10% urea. After one month of application of the formula, a second evaluation was carried out.

DRUG

Group 3. Placebo formula.

Participants included in this group after randomisation received a formulation with no active ingredients included in its composition and were assessed at baseline and after one month.

Trial Locations (1)

28040

Facultad de Enfermería, Fisioterapia y Podología de la Universidad Complutense de Madrid, Madrid

All Listed Sponsors
lead

Universidad Complutense de Madrid

OTHER

NCT07162454 - Effectiveness of CBD for Neuropathic Pain in Diabetic Foot Neuropathy | Biotech Hunter | Biotech Hunter